Overview

PET Study of Breast Cancer Patients Using [68Ga]ABY-025

Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
The study will evaluate [68Ga]ABY-025 for PET imaging of HER2 expression in subjects with HER2-positive or HER2-negative breast cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Biomedical Radiation Sciences
Collaborators:
Affibody
Swedish Cancer Society